Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We are in complete agreement with Bennett’s statement that a key consideration for a vCJD screening test of blood donations is specificity. Our study was designed to refine the confidence intervals of our previous estimate of 100%1 and was conducted with reference to the Common Technical Specification of the European Commission for acceptance of a vCJD blood test as fit for purpose, requiring 99.5% specificity in a cohort of 5000 samples.2
Jackson GS, Burk-Rafel J, Mead S, Collinge J. Blood Test for Variant Creutzfeldt-Jakob Disease—Reply. JAMA Neurol. 2014;71(8):1054–1055. doi:10.1001/jamaneurol.2014.1539
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: